AbbVie (NYSE:ABBV) Sets New 1-Year High - Here's What Happened

Key Points

• AbbVie shares reached a new 52-week high of $292.67, up from a previous close of $285.99, amid positive developments across its drug portfolio.
• The FDA accepted AbbVie’s application for etentamig for relapsed or refractory multiple myeloma, while approval of a home-based Skyrizi regimen for Crohn’s disease could expand the company’s immunology business and help offset Humira-related losses.
• Analysts maintain a broadly positive view, with a “Moderate Buy” consensus and a $279.86 target price, but some caution that the stock may be fully valued and faces future patent cliffs, rising expenses and stronger competition.

AbbVie Inc. (NYSE:ABBV - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $292.67 and last traded at $291.0470, with a volume of 377,371 shares traded. The stock had previously closed at $285.99.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie submitted a Biologics License Application to the FDA for etentamig, a monthly dosed BCMA × CD3 bispecific antibody for adults with relapsed or refractory multiple myeloma. The application is supported by a pivotal Phase 3 trial that met its primary endpoint, giving AbbVie another potential growth driver in oncology. AbbVie Submits Biologics License Application for Etentamig
• Positive Sentiment: FDA approval of a subcutaneous induction regimen for Skyrizi in Crohn’s disease gives patients a home-based treatment option and could improve the product’s commercial reach. Skyrizi and Rinvoq remain central to replacing revenue lost from Humira’s patent expiration. AbbVie Skyrizi Crohn’s Disease Approval
• Positive Sentiment: Income-focused coverage continues to highlight AbbVie’s dividend record and its potential for growth through immunology, oncology and aesthetics. That supports demand from defensive and dividend-oriented investors. Best Dividend Aristocrats for November 2026
• Neutral Sentiment: Investors are awaiting third-quarter results, with expectations focused on whether Skyrizi and Rinvoq can offset Humira-related pressure. Recent results showed revenue growth and an earnings beat, but upcoming guidance remains an important catalyst. AbbVie Heads Into Q3 Earnings
• Negative Sentiment: Analysts warn that AbbVie’s stock may be fully valued after its strong rally. The company faces a future patent cliff, rising expenses and intensifying competition, which could pressure estimates and limit near-term gains. AbbVie Patent Cliff Analysis

Analysts Set New Price Targets

A number of analysts have commented on the stock. Piper Sandler boosted their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a research note on Thursday, August 20th. Morgan Stanley upped their price objective on shares of AbbVie from $296.00 to $310.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 7th. Guggenheim reissued a "buy" rating and issued a $288.00 price target on shares of AbbVie in a report on Friday, October 9th. BMO Capital Markets raised their target price on AbbVie from $258.00 to $300.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Finally, Wall Street Zen cut AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Sunday, July 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $279.86.

AbbVie Stock Performance

The company has a market capitalization of $512.52 billion, a P/E ratio of 82.03, a price-to-earnings-growth ratio of 1.30 and a beta of 0.24. The business has a 50 day moving average of $268.20 and a 200-day moving average of $236.51.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. During the same quarter in the previous year, the firm earned $2.97 EPS. The company's quarterly revenue was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 13.92 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, October 15th. AbbVie's dividend payout ratio is currently 195.48%.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company's stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Burk Holdings LLC purchased a new stake in AbbVie in the 2nd quarter valued at approximately $30,000. Marquette Asset Management LLC grew its holdings in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after buying an additional 48 shares during the last quarter. Principia Wealth Advisory LLC increased its position in AbbVie by 38.9% during the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company's stock worth $40,000 after buying an additional 44 shares in the last quarter. IMG Wealth Management Inc. increased its position in AbbVie by 3,060.0% during the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company's stock worth $40,000 after buying an additional 153 shares in the last quarter. Finally, Tacita Capital Inc acquired a new position in shares of AbbVie in the second quarter worth $42,000. 70.23% of the stock is currently owned by institutional investors.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company's key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.